Stockholm, Sweden — Medivir AB (OMX: MVIR) is, as previously announced, conducting a reorganisation of the company’s management group which will, as of 1 March, comprise six people, including the President & CEO. Medivir has recruited two new people in order to strengthen important functions and generate an increased operational focus.
Christine Lind has been employed as the Executive Vice President, Strategic Business Development. She will have operational responsibility for the newly created Strategic Business Development function. Christine’s most recent position was as Vice President, Business Development at LifeCell Corporation in New York, and she also has twelve years of investment banking experience at Merrill Lynch & Co. and Gerard Klauer Mattison & Co. Christine studied Finance and Information Systems at New York University and also has a Master of Business Administration from Columbia Business School.
Ola Burmark has been employed as the Chief Financial Officer. His areas of responsibility include not only operational responsibility for the Finance & Administration function, but also responsibility for Investor Relations. Ola’s previous positions include that of CFO at OneMed AB and Aditro Holding AB. He has also worked as SVP Finance and M&A at Thule Group AB and Cell Network AB, as Cash Manager at AB SCA Finans, and as an auditor at Ernst & Young. Ola has a B.Sc. in Finance and Business Administration.
“I’m delighted to welcome Christine and Ola to Medivir. They both bring extensive experience and specialist skills that will be of huge benefit to us, now that we are accelerating our work on strategic implementation and long-term value generation within the company. I look forward to continuing this work in partnership with the new management group and other members of staff,” says Niklas Prager, President & CEO of Medivir AB.
For more information please contact:
Niklas Prager, CEO Medivir AB, phone +46 (0)8-407 64 30.
Medivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a growing portfolio of specialty care pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List.